Current status of thiopurine analogues in the treatment in Crohn's disease

Peter Laszlo Lakatos, Lajos S. Kiss

Research output: Contribution to journalReview article

5 Citations (Scopus)


In the last decades, with the development of biological therapy, the treatment paradigms in patients with Crohn's disease have continuously evolved. Several studies focusing on the optimal use of both traditional immunosuppressants and biological therapy have been published, investigating conventional, accelerated step-up and top-down approaches. In addition, much emphasis has been placed in recent years on the determination of important predictive factors that could enable early patient stratifcation, which would lead to a tailored management strategy. In this review, the authors try to highlight new evidence on the optimal timing, benefits, and risks of immunosuppressants alone, or in combination, in patients with Crohn's disease.

Original languageEnglish
Pages (from-to)4372-4381
Number of pages10
JournalWorld journal of gastroenterology
Issue number39
Publication statusPublished - Oct 21 2011


  • Azathioprine
  • Biologicals
  • Crohn's disease
  • Immunosuppressives
  • Thiopurine methyltransferase

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Current status of thiopurine analogues in the treatment in Crohn's disease'. Together they form a unique fingerprint.

  • Cite this